AEs |
Adverse events |
AJCC |
American Joint Committee on Cancer |
CRT |
Chemoradiotherapy |
CT |
Computed tomography |
CTLA-4 |
Cytotoxic T-lymphocyte-associated antigen 4 |
EGFR |
Epidermal growth factor receptor |
ESMO |
European Society of Medical Oncology |
ICI |
Immune checkpoint inhibitors |
IV |
Intravenous |
MPR |
Major pathological response |
NCCN |
National Comprehensive Cancer Network |
NSCLC |
Non small-cell lung cancer |
OS |
Overall survival |
pCR |
Pathological complete response |
PD-1 |
Programmed death 1 |
PD-L1 |
Programmed death-ligand 1 |
PET/CT |
Positron emission tomography/computed tomography |
PFS |
Progression-free survival |
RT |
Radiation therapy |
SUV |
Standardized uptake values |
TKI |
Tyrosine kinase inhibitors |
TMB |
Tumor mutational burden |
TNM |
Tumor, Node, and Metastasis staging system of American Joint Committee on Cancer |